share_log
Reuters ·  Dec 30, 2024 15:15
Sangamo Therapeutics to Regain Full Rights to Hemophilia a Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment